Spark Therapeutics (ONCE) Rating Increased to Buy at ValuEngine

ValuEngine upgraded shares of Spark Therapeutics (NASDAQ:ONCE) from a hold rating to a buy rating in a research report released on Monday, April 9th.

Other equities research analysts have also recently issued reports about the company. Mizuho set a $79.00 price objective on Spark Therapeutics and gave the company a buy rating in a research report on Thursday, March 29th. Credit Suisse Group reaffirmed an outperform rating and set a $75.00 price objective (up from $61.00) on shares of Spark Therapeutics in a research report on Thursday, March 8th. Raymond James Financial set a $66.00 target price on Spark Therapeutics and gave the stock a buy rating in a research report on Wednesday, February 21st. BMO Capital Markets set a $64.00 target price on Spark Therapeutics and gave the stock a buy rating in a research report on Wednesday, February 21st. Finally, Sanford C. Bernstein reissued a buy rating and issued a $60.00 target price (down from $71.00) on shares of Spark Therapeutics in a research report on Wednesday, February 21st. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, five have given a hold rating and seventeen have given a buy rating to the company. Spark Therapeutics currently has a consensus rating of Buy and a consensus price target of $70.58.

How to Become a New Pot Stock Millionaire

Shares of Spark Therapeutics stock opened at $77.79 on Monday. Spark Therapeutics has a 52 week low of $41.06 and a 52 week high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Tuesday, February 20th. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.73). Spark Therapeutics had a negative return on equity of 59.38% and a negative net margin of 2,100.80%. The business had revenue of $7.41 million during the quarter, compared to the consensus estimate of $9.53 million. equities analysts anticipate that Spark Therapeutics will post -3.33 earnings per share for the current fiscal year.

In other Spark Therapeutics news, COO John Furey sold 20,000 shares of Spark Therapeutics stock in a transaction on Thursday, April 12th. The stock was sold at an average price of $77.51, for a total transaction of $1,550,200.00. Following the completion of the sale, the chief operating officer now directly owns 20,000 shares of the company’s stock, valued at approximately $1,550,200. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 7.30% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Aperio Group LLC increased its position in Spark Therapeutics by 29.2% during the 4th quarter. Aperio Group LLC now owns 3,972 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 898 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in Spark Therapeutics by 5.0% during the 4th quarter. The Manufacturers Life Insurance Company now owns 21,428 shares of the biotechnology company’s stock valued at $1,102,000 after buying an additional 1,013 shares in the last quarter. Great West Life Assurance Co. Can increased its position in Spark Therapeutics by 47.3% during the 3rd quarter. Great West Life Assurance Co. Can now owns 3,939 shares of the biotechnology company’s stock valued at $351,000 after buying an additional 1,264 shares in the last quarter. Glenmede Trust Co. NA increased its position in Spark Therapeutics by 15.5% during the 4th quarter. Glenmede Trust Co. NA now owns 10,850 shares of the biotechnology company’s stock valued at $557,000 after buying an additional 1,456 shares in the last quarter. Finally, California State Teachers Retirement System increased its position in Spark Therapeutics by 3.8% during the 3rd quarter. California State Teachers Retirement System now owns 42,716 shares of the biotechnology company’s stock valued at $3,809,000 after buying an additional 1,570 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: This report was first reported by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://weekherald.com/2018/04/17/spark-therapeutics-once-upgraded-to-buy-at-valuengine.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply